Gilead Sciences, Inc. $GILD Shares Sold by Equitable Trust Co.

Equitable Trust Co. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 17,153 shares of the biopharmaceutical company’s stock after selling 292 shares during the quarter. Equitable Trust Co.’s holdings in Gilead Sciences were worth $1,902,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. TD Asset Management Inc increased its stake in Gilead Sciences by 44.7% in the 2nd quarter. TD Asset Management Inc now owns 3,420,676 shares of the biopharmaceutical company’s stock valued at $379,250,000 after buying an additional 1,056,474 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Gilead Sciences by 3.1% during the 2nd quarter. Revolve Wealth Partners LLC now owns 3,595 shares of the biopharmaceutical company’s stock worth $399,000 after purchasing an additional 108 shares during the period. Cornerstone Wealth Group LLC grew its stake in shares of Gilead Sciences by 20.1% during the 2nd quarter. Cornerstone Wealth Group LLC now owns 2,822 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 472 shares during the period. NorthRock Partners LLC grew its stake in shares of Gilead Sciences by 11.1% during the 2nd quarter. NorthRock Partners LLC now owns 12,922 shares of the biopharmaceutical company’s stock worth $1,433,000 after purchasing an additional 1,290 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its stake in shares of Gilead Sciences by 0.5% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 107,541 shares of the biopharmaceutical company’s stock worth $11,923,000 after purchasing an additional 500 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on GILD shares. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, Citigroup upped their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.08.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $118.48 on Wednesday. The stock has a market cap of $147.01 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 52 week low of $84.80 and a 52 week high of $121.83. The company’s 50-day moving average price is $114.84 and its 200 day moving average price is $110.35. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares in the company, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,000 shares of company stock worth $7,632,100. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.